Lee Willis C's Form 4 filing
Emmaus Life Sciences, Inc. (EMMA) · filed Jun 2, 2023
- Accession no.
- 0001209191-23-033573
- Filed
- Jun 2, 2023, 1:23 PM ET
- Trade date
- Sep 20, 2022-May 31, 2023
- Filing delay
- 255 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $8.53K. It was filed 255 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lee Willis CCIK 0001517775 | Director, Officer (COO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 20, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +750 | $0.28 | +$210 | 287,724 | Direct | |
| May 31, 2023 | Common stock, $0.001 par value | PPurchaseAcquired | +28,700 | $0.29 | +$8,323 | 30,600 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.